Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Efficacy of regional renal nerve blockade in patients with chronic refractory heart failure.

Dai QM, Fen Y, Lu J, Ma GS.

Chin Med J (Engl). 2013 Mar;126(6):1076-80.

PMID:
23506581
2.

Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.

Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, Hanna RD, Backes RJ, Mookadam F, Heublein D, Bailey KR, Burnett JC.

Am Heart J. 2005 Mar;149(3):541-7.

PMID:
15864245
4.

Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction.

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M.

J Am Coll Cardiol. 2005 Mar 1;45(5):661-7.

5.

[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].

Skvortsov AA, Mareev VIu, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Masenko VP, Belenkov IuN.

Ter Arkh. 2006;78(8):14-20. Russian.

PMID:
17078211
6.
7.

Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern.

Feola M, Aspromonte N, Milani L, Bobbio M, Bardellotto S, Barro S, Giovinazzo P, Noventa F, Valle R.

J Card Fail. 2008 Jun;14(5):420-5. doi: 10.1016/j.cardfail.2008.01.013. Epub 2008 May 27.

PMID:
18514935
8.

Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.

Kasama S, Toyama T, Sumino H, Matsumoto N, Sato Y, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M.

J Nucl Med. 2007 Dec;48(12):1993-2000. Epub 2007 Nov 15.

9.

[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].

Skvortsov AA, Mareev VIu, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Masenko VP, Belenkov IuN.

Ter Arkh. 2006;78(9):61-71. Russian.

PMID:
17076227
10.

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M.

J Am Coll Cardiol. 2001 Apr;37(5):1228-33.

11.

Prognostic impact of plasma brain natriuretic peptide for cardiac events in elderly patients with congestive heart failure.

Tamura K, Takahashi N, Nakatani Y, Onishi S, Iwasaka T.

Gerontology. 2001 Jan-Feb;47(1):46-51.

PMID:
11244291
12.

Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.

Sirithunyanont C, Leowattana W, Sukumalchantra Y, Chaisupamonkollarp S, Watanawaroon S, Chivatanaporn B, Bhuripanyo K, Mahanonda N.

J Med Assoc Thai. 2003 May;86 Suppl 1:S87-95.

PMID:
12866774
13.

[Acute hemodynamic effects of intravenous recombinant human brain natriuretic peptide in patients with acute myocardial infarction complicated with heart failure].

Li SQ, Fu XH, Liu J, Gu XS, Zhang J, Fan XN, Jiang YF, Miao Q.

Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Jan;34(1):23-7. Chinese.

PMID:
16626544
14.

Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST).

Frantz RP, Lowes BD, Grayburn PA, White M, Krause-Steinrauf H, Krishnan V, Uyeda L, Burnett JC; BEST Neurohumoral Substudy Investigators..

J Card Fail. 2007 Aug;13(6):437-44.

PMID:
17675057
15.

Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?

Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P.

Clin Sci (Lond). 2008 Feb;114(3):221-30.

PMID:
17688420
16.

High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.

Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M.

J Am Coll Cardiol. 2000 Nov 1;36(5):1587-93.

17.
18.

Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure.

Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW.

Circulation. 2006 Feb 21;113(7):977-85. Epub 2006 Feb 13.

19.

Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure.

Selvais PL, Robert A, Ahn S, van Linden F, Ketelslegers JM, Pouleur H, Rousseau MF.

J Card Fail. 2000 Sep;6(3):201-7.

PMID:
10997745
20.

Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.

Pitt B, Latini R, Maggioni AP, Solomon SD, Smith BA, Wright M, Prescott MF, McMurray JJ.

Eur J Heart Fail. 2011 Jul;13(7):755-64. doi: 10.1093/eurjhf/hfr034. Epub 2011 Apr 4.

Supplemental Content

Support Center